Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | MTOR | P42345 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.59 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.59 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.59 |
| ▸ | POLA1 | P09884 | 2/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15316783 | 1.00 | PDE3A (0.80) | PDE3APDE4DSLC29A1LMNAMTOR | |
| Phosphoric Acid SCHEMBL20769295 | 0.95 | PDE3A (0.73) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL1254191 | 0.95 | PDE3A (0.73) | PDE3APDE4DSLC29A1LMNAMTOR | |
| Phosphoric Acid SCHEMBL4576320 | 0.95 | PDE3A (0.73) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL17184312 | 0.91 | PDE3A (0.67) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL29574822 | 0.90 | PDE3A (0.71) | PDE3APDE4DSLC29A1LMNAMTOR | |
| Gemcitabine SCHEMBL6369622 | 0.89 | PDE3A (1.00) | PDE3APDE4DSLC29A1LMNAMTOR | |
| Gemcitabine SCHEMBL19526092 | 0.89 | PDE3A (1.00) | PDE3APDE4DSLC29A1LMNAMTOR | |
| Gemcitabine SCHEMBL12503065 | 0.89 | PDE3A (1.00) | PDE3APDE4DSLC29A1LMNAMTOR | |
| Gemcitabine SCHEMBL20827751 | 0.89 | PDE3A (1.00) | PDE3APDE4DSLC29A1LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2221 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122095093-A | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122081200-A | Totipotent stem cell culture medium | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139251-A1 | RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260132406-A1 | RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260092276-A1 | Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions, and therapeutic applications | KYLONOVA XIAMEN BIOPHARMA CO LTD (CN) | 2026-04-02 | — | — | US | claimed |
| US-12582668-B2 | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) | Arrowhead Pharmaceuticals, Inc. (US) | 2026-03-24 | — | — | US | claimed |
| US-20260078375-A1 | RNAi Agents for Inhibiting Influenza A Viral Gene Expression, Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3573623-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF FACTOR XII GENE EXPRESSION | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-04 | — | — | EP | claimed |
| US-20260053941-A1 | MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2026-02-26 | — | — | US | claimed |
| US-12553050-B2 | Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-02-17 | — | — | US | claimed |
| US-20080221053-A1 | RNA APTAMERS AND METHODS FOR IDENTIFYING THE SAME | REGADO BIOSCIENCES, INC. | 2008-09-11 | — | — | US | claimed |
| US-20080125386-A1 | RNA interference agents for therapeutic use | UNIVERSTIY OF MASSACHUSETTS (US) | 2008-05-29 | — | — | US | claimed |
| US-20070292408-A1 | Spinal Muscular Atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | UNIVERSITY OF MASSACHUSETTS (US) | 2007-12-20 | — | — | US | claimed |
| EP-1556402-A4 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | UNIV MASSACHUSETTS (US) | 2007-10-10 | — | — | EP | claimed |
| WO-2007092182-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-16 | — | — | WO | claimed |
| WO-2007089607-A2 | RNA SILENCING AGENTS FOR USE IN THERAPY AND NANOTRANSPORTERS FOR EFFICIENT DELIVERY OF SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-09 | — | — | WO | claimed |
| US-20060036087-A1 | 2'-deoxy-2'-fluoro modified RNA | RIBOZYME PHARMACEUTICALS, INC. | 2006-02-16 | — | — | US | claimed |
| EP-1556402-A2 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | University of Massachusetts (US) | 2005-07-27 | — | — | EP | claimed |
| US-20050020521-A1 | Rna interference strands and antibody strands | UNIVERSITY OF MASSACHUSETTS (US) | 2005-01-27 | — | — | US | claimed |
| WO-2004029212-A2 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2004-04-08 | — | — | WO | claimed |